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Summary
Objective: Meta-analysis of randomized controlled trials (RCTs) e of a hip powder of Rosa canina (rosehip) preparation for symptomatic
treatment of osteoarthritis (OA), in order to estimate the empirical efﬁcacy as a pain reducing compound.
Method: RCTs from systematic searches were included if they explicitly stated that OA patients were randomized to either rosehip or placebo.
The primary outcome was reduction in pain calculated as effect size (ES), deﬁned as the standardized mean difference (SMD). As secondary
analysis the number of responders to therapy was analyzed as Odds Ratios (OR), and expressed as the Number Needed to Treat (NNT).
Restricted Maximum Likelihood (REML) methods were applied for the meta-analyses using mixed effects models.
Results: The three studies (287 patients and a median trial-duration of 3 months) e all supported by the manufacturer (Hyben-Vital Interna-
tional) e showed a reduction in pain scores by rosehip powder (145 patients) compared to placebo (142 patients): ES of 0.37 [95% conﬁdence
interval (CI): 0.13e0.60], P¼ 0.002. Test for homogeneity seemed to support that the efﬁcacy was consistent across trials (I 2¼ 0%). Thus it
seems reasonable to assume that the three studies were measuring the same overall effect. It seemed twice as likely that a patient allocated to
rosehip powder would respond to therapy, compared to placebo (OR¼ 2.19; P¼ 0.0009); corresponding to a NNT of six (95% CI: 4e13)
patients.
Conclusions: Although based on a sparse amount of data, the results of the present meta-analysis indicate that rosehip powder does reduce
pain; accordingly it may be of interest as a nutraceutical, although its efﬁcacy and safety need evaluation and independent replication in
a future large-scale/long-term trial.
ª 2008 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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Osteoarthritis (OA) is a common joint disorder and may
occur in any synovial joint in the body, although the condi-
tion is most common in hands, knees, hips and spine1.
The clinical problems, along with the pathological and radio-
graphic changes, include joint pain, stiffness, movement
with a restricted range and cracking of joints (crepitus)2.
OA has traditionally been regarded as a non-inﬂammatory
condition3, but improved detection methods show that
inﬂammatory pathways are up-regulated in OA4; with,
e.g., a low-level increase by groups in C-reactive protein
(CRP)5. Drug therapy in OA consists mainly of analgesics
and non-steroidal anti-inﬂammatory drugs (NSAIDs).
Paracetamol is the oral analgesic of ﬁrst choice, and if suc-
cessful, the preferred long-term oral analgesic. However,
NSAIDs must be considered in patients with no response*Address correspondence and reprint requests to: Professor H.
Bliddal, The Parker Institute, Frederiksberg Hospital, DK-2000 F,
Denmark. Tel: 45-38164151; Fax: 45-38164159; E-mail: henning.
bliddal@frh.regionh.dk
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965to paracetamol6,7. Disease-modifying OA drug (DMOAD)-
therapy remains to be developed in order to slow down
disease progression as demonstrated by, e.g., a reduced
joint space narrowing on plain X-rays8.
According to the consensus statement following the
outcome measures in rheumatology (OMERACT) III con-
ference, a core set of outcome measures for phase III
clinical trials pointed towards four variables which should
be evaluated in trials with patients suffering from either
knee, hip, or hand OA: pain, physical function (i.e., dis-
ability), patient global assessment; and e for studies of
1 year or longer e joint imaging9. It is mandatory to per-
form continuous follow-up on clinical interventions, which
are assessed on scales typically referred to as
subjective10,11.
A standardized hip powder of Rosa caninamade from the
seeds and husks of the fruits from a subtype of R. canina
hip powder (i.e., rosehip), the common wild-briar hedgerow
rose, has been evaluated in (short-term) randomized
controlled trials (RCTs)12. According to the best-evidence
synthesis, there are contradictory results with regard to
scientiﬁc evidence for R. canina extracts13. Evidence from
early in vitro studies indicates that R. canina hip powder
966 R. Christensen et al.: Does the hip powder of Rosa canina reduce pain in OA patients?preparations exert anti-inﬂammatory properties via reduced
chemotaxis of peripheral blood neutrophils and monocytes
in healthy subjects, and a reduction in CRP is seen after
4 weeks supplementation in patients with OA14,15. The
proposed mechanism of action has been focused on the
preparations’ anti-oxidative capacities, and a speciﬁc galac-
tolipid (called GOPO) has been identiﬁed (in vitro) as anti-
inﬂammatory, and as such possibly the reason for the
preparation’s proposed pain reducing property16. These
considerations over active ingredients have recently been
conﬁrmed by others, as extracts of R. canina fruits have
shown potent anti-inﬂammatory and anti-nociceptive activi-
ties17 and R. canina hip powder extracts (an organic sol-
vent) may inhibit both cyclooxygenase (COX)-1 and -218.
In a clinical trial it has been shown that R. canina hip pow-
der may have some efﬁcacy in hip and knee OA patients19.
In the present systematic review on clinical efﬁcacy of
giving a R. canina hip powder preparation for symptomatic
treatment of OA, with explicit meta-analysis of the available
RCTs20 e our primary aim was to obtain up-to-date, evi-
dence-based estimates that could provide a detailed view
of the symptomatic efﬁcacy of R. canina compounds used
in the treatment ofOA. The results of this analysismay be cru-
cial for the evaluation whether or not these preparations will
be relevant for future large-scale (i.e., phase III) clinical trials.Materials and methods
Study selection, assessment of eligibility criteria, data extraction, and sta-
tistical analysis were performed based on a predeﬁned protocol according to
the Cochrane Collaboration guidelines (http://www.cochrane.org/resources/
handbook/index.htm).RETRIEVAL OF PUBLISHED STUDIESRCTs of R. canina hip powder treatment vs placebo were identiﬁed
through a systematic literature search in the following bibliographic data-
bases: Medline via PubMed (mid 1950s to October 2007), EMBASE via
WebSpirs (1980 to October 2007), CINAHL via WebSpirs (1982 to October
2007), Biosis Previews via WebSpirs (1980 to October 2007), Web of Sci-
ence (1945e54 to October 2007), Sciﬁnder (1907 to October 2007), Scopus
(1966 to October 2007), and the Cochrane Library from 1966 to October
2007. Following the searches, reference lists of original reports and review
articles retrieved through the described searches, were thoroughly checked
for further relevant studies. Finally, we searched conference abstracts over
the past 2 years via the established international societies of rheumatology,
i.e., the OsteoArthritis Research Society International (OARSI), EUropean
League Against Rheumatism (EULAR) and the American College of Rheu-
matology (ACR). Since the available studies were expected to be few,
a broad, less speciﬁc search strategy was applied: (Rosehip OR ‘‘Rose
hip’’ OR ‘‘Rosa canina’’ OR ‘‘dog rose’’ OR Rosaceae OR Litozin OR hyben
OR GOPO OR i-ﬂex) AND (OA OR osteoarthrosis). Controlled, randomized
and clinical trials were deliberately not part of an explicit search strategy,
since we wished to ﬁnd any work dealing with R. canina hip powder in the
treatment of OA. With the awareness of a higher proportion of noise in the
chosen searches, full references were reviewed for possible RCTs, and
full text references were obtained for further scrutiny, where relevant.INCLUSION AND EXCLUSION CRITERIAWe included RCTs comparing a preparation containing R. canina hip
powder with a placebo intervention. Studies were selected if the included
patients were (explicitly) described as having clinical or radiographic evidence
of OA. Two reviewers (RDA, HB) crosschecked and agreed on diagnostic
criteria in each trial. We excluded studies in conditions such as non-OA joint
pain, rheumatoid arthritis (RA), pain due to surgery or injury, and studies
with mixed patient groups such as those with both OA and RA, unless the
subgroup data for OA were available. No language restrictions applied.QUALITY ASSESSMENTThe quality of studies was assessed based on randomization, mask-
ing and withdrawal. The complete reports of the RCTs that were selectedfor inclusion in the meta-analysis were scored by two reviewers for
quality (RC, EMB) using a validated instrument21. The score was given
as follows: if the study was described as randomized (þ1); if the study
was described as double masked (þ1); if there was a (detailed) descrip-
tion of withdrawals and attrition rates/detailed outcome data and the
analysis was performed according to the intention-to-treat (ITT) principle
(þ1). In addition, if the random allocation and the double blinding were
properly described and appropriately put into practice, each item
received 1 point extra. Conversely, if the methods (randomization and
masking) were not considered appropriate, 1 point was subtracted
from each item.DATA EXTRACTION AND OUTCOME MEASURESTwo reviewers (RC, EMB) undertook data extraction independently.
Disagreements were resolved by discussion. A customized form was
used to record the following: authors of the study, year of publication,
trial design, study length, number of patients randomized (i.e., the ITT
population, Ntotal), the number of patients for whom detailed outcome
data was available for meta-analysis in each group (E/exposed¼R. can-
ina hip powder and C/control¼ placebo) included in the individual-study
statistical tests (NE and NC, respectively), average patient age, sex, site
of OA. Note that in order to estimate the relative number of responders to
therapy, we included the ITT population (based on the NEITT and
NCITT, respectively) in the denominator. The number of responders
per se, was assessed as the number of patients in each trial deﬁned
by the authors as being a responder; the number of responders in
both the R. canina hip powder and placebo group were based on the
same criterion11.
As it seemed relevant to consider the available efﬁcacy in cross-over trials
as being subjected to carry-over bias19, we only report (i.e., include) data
from the ﬁrst period. The primary outcome measure was the magnitude of
pain reduction22. The secondary outcomes were the reported changes in
the average level of applied painkillers; the extracted (or estimated) reported
number of responders per group following intervention11. Disability and
patient’s global assessment following therapy9 were not included as out-
comes in the present meta-analysis, since we expected that these endpoints
would not have been reported consistently.STATISTICAL ANALYSISAs a preliminary review of the available data23 supported the notion
that the available cross-over trials had been reporting carry-over bias24,
we chose to include only data from the ﬁrst period, as any pooled efﬁcacy
meta-analysis including data from both periods would imply a risk of
(accumulating) carry-over bias25,26. For each of the continuous outcomes
(i.e., pain and rescue medications), we calculated the test statistics based
on the available data, using standard formulae26,27. Based on these
statistics and the number of observations in each group, we were able
to estimate the standardized mean difference (SMD) for each study28 e
which was applied as effect size (ES)29. The corresponding variance
(SE2) was calculated based on the individual study SMD and the number
of patients included (SE2¼ 1/NEþ 1/NCþ SMD2/[2{NEþNC}])28. As the
unadjusted (Cohen’s) SMD in principle does not treat the variance
(SE2) as an estimate, we applied (i.e., via multiplication) the Hedges’
bias-correction (J¼ 1 3/[4 df 1]; i.e., df¼NEþNC 2) by default e
adjusting for small sample bias30. SMDs were signed so that positive
values (>0) indicated a beneﬁt of R. canina hip powder: clinically,
jESj  0.2 is considered small, jESj  0.5 is moderate (and would
probably be recognized clinically31), and jESj  0.8 is large6,7,32,33. The
Odds Ratio (OR) was estimated for the dichotomous efﬁcacy data (i.e.,
responders to therapy)34. To combine the individual study results we
did (generic inverse variance) meta-analyses via mixed effects model
procedures using SAS software (version 9.1.3, by SAS Institute Inc.,
Cary, NC, USA)35. We applied the restricted maximum likelihood
(REML) method36,37 to estimate the between study variance and the
combined efﬁcacy28,38. The heterogeneity (between trials) was examined
with a standard Q test (testing the hypothesis of homogeneity: c(k1)
2 )39.
However, as measures of the extent of heterogeneity might be considered
preferable to test of its presence, we evaluated possible inconsistency
between effect measures via the I2 statistic40 e which can be interpreted
as the percentage of variability in effect estimates due to heterogeneity41.
As it is often sensible to use one statistic for meta-analysis and re-express
the results using a second more easily interpretable statistic26, we esti-
mated the Number Needed to Treat (NNT), with 95% conﬁdence intervals
(CI) on the basis of the combined OR value42, since this method enables
direct translation into clinical practice10,43,44; applying the overall event
rate in the placebo group as a proxy for baseline risk45,46. The software
‘‘Visual Rx’’ is designed to calculate NNT (and NNH) from the pooled
results of a meta-analysis and produce a graphical display of the result47:
http://www.nntonline.net/ebm/visualrx/try.asp48.
967Osteoarthritis and Cartilage Vol. 16, No. 9ResultsCHARACTERISTICS OF TRIALSThe Quality of Reporting of Meta-analyses (QUOROM)-
recommended ﬂowchart20 in Fig. 1 displays the eligibility
details of the studies identiﬁed by the combined search
strategy. Studies with clearly irrelevant objectives/designs
as well as abstracts and reviews/theme articles, were
separated from possible studies for inclusion: initially the
search strategy revealed 37 potential references, which
were considered at abstract level. When removing obvi-
ously residual literature and abstracts later reported in full,
we retrieved 15 studies for further scrutiny e including
critical assessment of the reported references12e19,49e55.
Among these, ﬁve papers were excluded as a conse-
quence of being reviews12,13,50,54,55; one study only
considered intestinal microﬂora in patients with irritable
bowel syndrome49; three studies were categorized as
in vitro16e18. Among the remaining six potentially relevant
studies14,15,19,51e53 two were excluded as a consequence
of being controlled trials, reported as case-control trials
with explicit focus on in vitro-inﬂammatory properties14,
and inhibition of chemotaxis and chemiluminescence15,
respectively. This left four trials19,51e53 potentially relevant
for inclusion in the meta-analysis23. However, following
personal contact with Dr Winther and Dr Rein, it appeared
that the patent registration from Rein et al.51 was based on
an unpublished subgroup-analysis of the Norwegian study52
and was, quote: ‘‘a rehash of a another study’’. Accordingly,
we were able to include three (assumed) mutually indepen-
dent RCTs19,52,53.
Table I shows the baseline characteristics of the included
studies. All trials were supported by Hyben-Vital Interna-
tional (Tullebølle, Langeland, Denmark): one study was
performed in an outpatient clinic in Norway52, while the
two others included patients (from outpatient clinics) in
Denmark19,53. Overall, the trials randomized 306 OA
patients to either R. canina hip powder or placebo, allocat-
ing 153 patients to each group. The Danish trials19,53
applied a cross-over design, and excluded patients withPotentially relevant studies identified and
screened for retrieval (k
0 
= 15)
Trials retrieved for more detailed evaluation
(k1 = 6)
Studi
• Rev
• In v
• Pati
Potentially appropriate RCTs
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Fig. 1. Flow chart of the search strother rheumatic diseases than OA, and those who received
glucosamine or intra-articular glucocorticoids 6 weeks prior
to the study. The Norwegian study52 included OA patients
with pain for at least 6 months, who were on a waiting list
for either hip or knee surgery, or on a list for ﬁnal evaluation
for surgery. As presented in Table I the majority of the
participating patients were women (62%) suffering from
knee OA (61%) with a median age of 66 years.PAIN REDUCTIONAs presented in Fig. 2(A): the meta-analysis of the three
studies reporting changes in pain scores produced a statis-
tically signiﬁcant (P¼ 0.0019) combined ES of 0.37 (95%
CI: 0.13e0.60) e favoring R. canina hip powder compared
to placebo. Test for homogeneity seemed to support that
the efﬁcacy was consistent across trials (Q¼ 0.18; I2¼
0%). Thus, it seems reasonable to assume that the three
(mutually independent) studies measured the same overall
effect. Apparently the pain reducing property of R. canina
hip powder seemed more pronounced in the population
examined in the study by Warholm et al.52, which included
patients who were on a waiting list for either hip or knee
surgery, or on a list for ﬁnal evaluation for surgery.USE OF RESCUE MEDICATIONAs presented in Fig. 2(B): the meta-analysis of the three
studies reporting changes in the use of ‘rescue medica-
tion’ produced a statistically signiﬁcant (P¼ 0.018)
combined ES of 0.28 (95% CI: 0.05e0.51) e favoring
R. canina hip powder compared to placebo. Test for
homogeneity seemed to support that the efﬁcacy was con-
sistent across trials (Q¼ 1.25; I 2¼ 0%). Thus it seems
reasonable to assume that the three (mutually indepen-
dent) studies measured the same overall effect. Appar-
ently R. canina hip powder did not reduce the patients’
consumption of painkillers in the population reported by
Warholm et al. (i.e., ES< 0.2)52, while based on the dia-
ries of the consumption of ‘rescue medication’ investigatedes excluded because of:
iew article (5)
itro study (3)
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968 R. Christensen et al.: Does the hip powder of Rosa canina reduce pain in OA patients?in the study by Winther et al.19 e the use of R. canina hip
powder resulted in a signiﬁcantly reduced use of analge-
sics, compared to placebo.NUMBER OF RESPONDERS TO THERAPYIn order to assess this secondary outcome, the arbitrary
‘‘responders to therapy’’, the following data was extracted:
(1) Warholm et al. used a simple yes-or-no questionnaire
(about relief of pain) after 4 months therapy in both groups52
(R. canina hip powder: 31/50 vs placebo: 21/50); (2) Rein
et al. deﬁned a responder as one who showed at least
one category of pain improvement53 (R. canina hip powder:
31/56 vs placebo: 18/56); (3) Winther et al. used any reduc-
tion in western ontario and mcmaster (WOMAC) score for
joint pain after the initial 3 weeks of treatment as a response
criterion e however, they did not report any explicit num-
bers following 3 months treatment19. We assessed the
number of responders (any reduction in WOMAC pain)
in each group following a Monte-Carlo simulation based
on the reported means and standard deviations (SDs)
(i.e., table 319) assuming that a univariate normal distribu-
tion apply56 (R. canina hip powder: 32/47 vs placebo: 26/
47). As presented in Fig. 2(C): the meta-analysis of the
studies reporting the number of patients responding to ther-
apy as a dichotomized (yes/no) count, produced a statisti-
cally highly signiﬁcant (P¼ 0.00089) combined OR of 2.19
(95% CI: 1.38e3.48) e favoring R. canina hip powder com-
pared to placebo; i.e., it is more than twice as likely that
a patient allocated to R. canina hip powder will respond to
therapy, compared to placebo. Test for homogeneity
seemed to support that the observed efﬁcacy was consis-
tent across trials (Q¼ 0.52; I 2¼ 0%), supporting the as-
sumption that the three (mutually independent) studies
were measuring the same overall effect. In absolute terms:
the total number of responders (across the three trials) on
R. canina hip powder and placebo was 94/153 (61.4%)
and 65/153 (42.5%), respectively. On the basis of the aver-
age number of responders within the placebo groups, the
combined OR corresponded to a NNT of six (95%
CI: 4e13) patients.ADVERSE EVENTS AND SAFETY CONSIDERATIONSFocusing on adverse events, there seemed to be the
same amount of mild cases of gastrointestinal discomfort
after intervention vs control52. The same number of patients
seemed to experience ‘acid regurgitation’ in both the study
by Rein et al.53 and Winther et al.19: one case in each group
(R. canina hip powder and placebo) e both leading to dis-
continuation. In the study by Winther et al.19, mild unwanted
effects (reported as being non-signiﬁcant) that did not cause
withdrawal, were explicitly reported; based on these data
we re-calculated empirical OR-values with 95% (‘‘exact’’57)
conﬁdence limits for these rare incident cases58: (1)
‘Frequent voiding’ [OR¼ 3.07 (0.24e162.65)]; (2) ‘Diarrhea’
[OR¼ 1.00 (0.07e14.07)]; (3) ‘Constipation’ [OR¼ 2.02
(0.10e120.54)]; (4) ‘Short episode of mild urticaria’ [OR¼
2.02 (0.10e120.51)].Discussion
The main result of our analysis was a small to moderate
short-term efﬁcacy of preparations with R. canina hip pow-
der with a small but clinically relevant reduction of pain in
-0.8 -0.6 -0.4 -0.2 0.0 0.2 0.4 0.6 0.8
Effect Size (SMD)
Warholm (2003)
Rein (2004)
Winther (2005)
Combined (Pain)
Warholm (2003)
Rein (2004)
Winther (2005)
Combined (Rescue medication)
Favors Placebo
ES = 0.37
(0.13 to 0.60)
ES = 0.28
(0.05 to 0.51)
A
B
Combined (Responders)
OR = 2.19
(1.38 to 3.48)
C
0.1 1.0 10.0
Odds Ratio
Warholm (2003)
Rein (2004)
Winther (2005)
2 
= 1.25; I2 = 0%; Z = 2.37 (P = 0.018)
= 0.52; I2 = 0%; Z = 3.33 (P = 0.00089)χ 2
2 
= 0.18; I2 = 0%; Z = 3.10 (P = 0.0019)
Favors Rosehip
Fig. 2. Efﬁcacy of R. canina hip powder (i.e., Rosehip) compared to placebo in OA patients presented as SMDs and OR. (A) Change (i.e.,
reduction) in self-reported pain; (B) change (i.e., reduction) in self-reported use of analgesics; (C) the number of patients deﬁned/estimated
as being a responder. Every square represents the individual study’s effect measure with 95% CI indicated by horizontal lines. Square sizes
are proportional to the precision of the estimate. The overall estimate from the meta-analysis and its CI are shown at the bottom of each
subplot (AeC), represented as a diamond. The center of the diamond represents the pooled point estimate, and its horizontal lines represent
the CI.
969Osteoarthritis and Cartilage Vol. 16, No. 9OA patients. However, the available data are sparse, since
we had only three clinical trials evaluating the efﬁcacy in
145 patients after use of R. canina hip powder for 3e4
months. One assumption that is prudent in order to make
statistical inference following meta-analysis, is that the
eligible studies included can be assumed to be mutually
independent, which might be an issue within the context
of clinical efﬁcacy of R. canina hip powder. Dr Rein had
access to the original data from Warholm et al.52 e enabling
a patent registration51 prior to the publication by Rein
et al.53; recalling that Dr Winther was the co-author on
this paper53 before the Winther et al. paper was published
in 200519. However, meta-analyses are depending on the
international peer-review system, which has been applied
in all of the included papers19,52,53. A combined analysis
(i.e., meta-analysis) of homogeneous results, quantiﬁes
the magnitude of clinical efﬁcacy per se59. Thus, it seems
possible that the empirical magnitude of clinical efﬁcacy
following use of R. canina hip powder is comparable to
other nutraceuticals available60. Our meta-analysis
supports the conclusion previously stated by Chrubasik:
‘‘Moderate evidence exists for the use of a powder of the
seeds and husks of a Rosa canina subspecies in patients
suffering from osteoarthritis’’12.We are conﬁdent that the efﬁcacy estimate is robust per
se, as it is based on very consistent ﬁndings (I2¼ 0%) e
thus, a new trial (of the same duration) would be expected
to result in a similar magnitude of small to moderate clinical
efﬁcacy (ES 0.4). In an (assumed) average knee OA pop-
ulation61,62, this ES would correspond to a mean reduction
in the visual analog scale (VAS) for pain (0e100 mm) of
6 mm; i.e., approximately 10% pain reduction. Apparently
the use of R. canina hip powder leads to a signiﬁcant reduc-
tion in the use of rescue medication, corresponding to
a small clinical efﬁcacy. This does not allow more detailed
interpretation, although it seems likely that a reduction in
analgesics could have an impact on a major public health
scale63. When focusing on the explicit, although arbitrary
outcome ‘responders to therapy’, it seems that an OR of
2.19 corresponding to an ES of 0.4364 e indicates a small
to moderate clinical efﬁcacy6,7,33. When translated into the
number of patients who would need R. canina hip powder
therapy (compared to placebo) in order to ‘‘treat’’ one pa-
tient, the combined estimated NNT was six patients. The
magnitude of R. canina hip powder as a pain reducing
agent is more pronounced than the primary analgesic of
choice in clinical practice, paracetamol/acetaminophen,
which compared to placebo has an ES of 0.13 (95% CI:
970 R. Christensen et al.: Does the hip powder of Rosa canina reduce pain in OA patients?0.04e0.22), and thus of questionable clinical signiﬁcance65.
Hence R. canina hip powder might have an impact as an
over-the-counter (OTC) preparation in the future. The pa-
tients studied in the present meta-analysis (see Table
I)19,52,53 represent a fairly homogenous OA population
with a clinically relevant age distribution. The exact degree
of OA (i.e., radiographic data) was not given in the studies,
in one study52, however, patients were presumably end-
stage, which might be the reason for a continuous use of
pain medication in this study, in spite of a signiﬁcant effect
of R. canina hip powder on self-reported pain.
An increasing interest has been noted over the last years
for dietary supplements for OA54 with a special emphasis
on glucosamine and chondroitine66,67. Glucosamine only
shows signiﬁcant efﬁcacy in Rottapharm-supported pivotal
trials, of which three well conducted trials had a pooled
efﬁcacy of ES¼ 0.27 (95% CI: 0.12e0.43)68. Never the
less the efﬁcacy of glucosamine has been heavily debated,
among many things because of the great heterogeneity
between efﬁcacy outcomes69e71.
In the present analysis of R. canina hip powder, the lack
of heterogeneity between studies gives credit to an efﬁcacy.
The drawback of this observation is e as with the Rotta-
pharm product e that the same company sponsored all
three studies on R. canina hip powder. Ideally, other similar
products from other manufacturers should be tested to sub-
stantiate the outcome or even better, the presumed active
ingredient (e.g., GOPO) should be isolated, patented, and
tested in a strictly controlled clinical trial, following guide-
lines for Good Clinical Practice (GCP) and consolidated
standards of reporting trials (CONSORT)72. Such initiatives
would increase the external validity of any proposed herbal
therapy73. Patients with chronic painful diseases seek
complementary-alternative therapy for various reasons.
Ramsey et al. has previously reported from a US cohort,
that alternative medicine use is highly prevalent among
those with OA (47%) and that levels of expenditure for
those who do consume these services ($1,127 per year)
approximate expenditures on more traditional medical
care ($1,148 per year)74. The traditional medical approach
has only been able to offer slight improvements with regard
to pain65,75 with a deﬁnite problem of a rather frightening list
of adverse events75,76. In contrast, alternative medications
are repeatedly found (i.e., report) to have almost no adverse
effects; this has been shown for both glucosamine77, chon-
droitin78, avocado/soybean unsaponiﬁables (ASU)79 among
many e as well as R. canina hip powder.
We turn to the question: whether treatment of OA via
prescription of anti-oxidants is dream or reality?80 In a short-
term cross-over trial 1 g of calcium ascorbate for either knee
or hip OAwas given for 14 days, resulting in a small to moder-
ate (statistically signiﬁcant) pain reduction compared to
placebo81, which is equivalent to our results for R. canina hip
powder. It is, however, noteworthy that data have been pre-
sented that the anti-inﬂammatory properties of R. canina hip
powder is unrelated to its vitamin C content14,15. In regard to
anti-oxidants, however, a recent large-scale meta-analysis
found that treatment with b-carotene, vitamin A, and vitamin
Emay increasemortality,while a potential role for vitaminC re-
mains to be clariﬁed82. By consequence, large-scale trials on
anti-oxidants are still relevant, and no ﬁnal conclusion may
be drawn regarding safety.
Alternative therapy should be subjected to a similar
scrutiny of effect vs adverse effects as ordinary medica-
tions42,83. The alternative OTC market is huge74 whether
it is efﬁcacious or not54, and with an inevitable inﬂuence
on both direct and indirect costs84. With regard to R. caninahip powder a large-scale trial is justiﬁed by the magnitude of
clinical efﬁcacy demonstrated in this meta-analysis of short-
term trials e an efﬁcacy in the area of 0.4 SMD-points. In
a parallel group design this would correspond to 133 OA
patients in each group in order to assess a statistically
signiﬁcant effect (P< 0.05, two-tailed) with a proper statisti-
cal power (90%)85. In order to monitor the clinical efﬁcacy
applying these R. canina hip powder products, the next
RCT should be of at least half a year duration, although
a 1-year trial with sufﬁcient imaging would be even better9.
We emphasize the need for future studies applying empiri-
cally validated outcomes (e.g., WOMAC86, knee and osteo-
arthritis outcome core (KOOS)87 or the Lequesne
index88)11, and that these studies explicitly report the num-
ber of so-called responders according to the OMERACTe
OARSI response criterion11,89. Also, a study should strictly
adhere to the CONSORT statement72,73,90, and be
subjected to central registration (e.g., http://www.
clinicaltrials.gov).
In conclusion, the dry powder of R. canina L. fruit (i.e.,
R. canina hip powder) seems to have a consistent, small
to moderate efﬁcacy on pain in OA patients; however, an
efﬁcacy only observed in short-term clinical trials (3e4
months). The adverse events were similar to placebo in
the available literature, and it seems safe to apply this
herbal remedy, though long-term safety remains to be
tested. The results of the present meta-analysis e that
R. canina hip powder does reduce pain e should be further
substantiated in a large-scale (i.e., phase III) trial.Conﬂicts of interest
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